Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
about
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisImpact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance.Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill StudiesPharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats.Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.The effect of antibiotics on bone healing: current evidence.The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Wolbachia pipientis growth kinetics and susceptibilities to 13 antibiotics determined by immunofluorescence staining and real-time PCR.Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin as a single injection for Pasteurellaceae respiratory infections in cattle using population pharmacokinetics and Monte Carlo simulations.Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.Impact of AAC(6')-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli.Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.Quinolone Resistance Reversion by Targeting the SOS Response.P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis.In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin.Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats.Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections.
P2860
Q30834393-0C55899D-0EB5-462E-8722-19E8998D171CQ35005817-F848C0ED-1544-45E6-B108-990649190583Q35676675-02E23C94-0687-451B-A11B-D2DACAC84434Q36039472-2B8E3BDB-807C-4296-B9DE-BA2F7EFEC4EBQ36163141-55629CDA-602B-4789-A61C-B9EE69925694Q36204123-933740E0-7301-4FCF-A779-60172DD7C092Q37335894-1EE4EE4C-4D27-4DD5-9A9E-DEEFC7F8EE14Q37346929-0FA6B282-A3EF-4CB0-B930-C9F7557C8DB3Q37392904-A454BAAB-D6DC-48C2-A4FB-6B34A8832303Q37913390-FAD618FD-264E-4F05-A510-58C64A2020CBQ37952621-276E3128-603B-4FD1-AB25-332D0FD16CD1Q38665480-99923022-5F3A-43B7-86BF-5285FDB96979Q39456569-CE6B6843-2F65-4312-B743-408E69C403A6Q39746369-E4EAC692-7243-49FD-ADA6-F977DE968A5DQ40199060-82E436C7-F510-4CFE-A573-EBA8846EE9B8Q40584376-85206024-4424-448C-B807-8FEB0C31DABBQ40587123-26EE6051-F7CE-43AE-A784-5E4E1352A825Q41453107-F116185C-2C34-4684-9861-1121D4C4711FQ42264036-A5011BC4-651F-4800-B3E6-37256A7EC64CQ43075165-EFBBAA8E-6BD2-444B-8825-7A9C4B2BC50EQ43751132-8726FC7E-AC9A-46D1-B288-32407E18E67AQ44251215-5C444016-C59D-42AA-A079-74D27BC95263Q45273479-D1F772A7-AAB7-4BFD-B049-C6DA371A36DBQ54296506-E9DE033E-8592-43C9-AE00-E2E6AA2967E5
P2860
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@ast
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@en
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@nl
type
label
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@ast
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@en
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@nl
prefLabel
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@ast
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@en
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@nl
P356
P1476
Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
@en
P2093
Schentag JJ
P356
10.1086/314059
P407
P478
31 Suppl 2
P577
2000-08-01T00:00:00Z